Two-dose combined vaccination against hepatitis A and B in healthy subjects aged 11-18 years

Scandinavian Journal of Gastroenterology

Volumn 34, Issue 12, 1999, Pages 1236-1240

  Van Herck, Koen ^a,b   Van Damme, P ^a,b   Collard, F ^a,b   Thoelen, S ^a,b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Adolescents; Clinical trial; Combined vaccine; Hepatitis A; Hepatitis B; Immunogenicity; Reactogenicity

Indexed keywords

HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MIXTURE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS A; HEPATITIS B; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION;

EID: 0033373733     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655299750024760     Document Type: Article

References (12)

1. 1. Hadler SC. Global impact of hepatitis A virus infection; changing patterns. In: Hollinger FB, Lemon SM, Margolis H, editors. Viral hepatitis and liver disease. Baltimore: Williams and Wilkins; 1991. p. 14-20.
2. 2. Maynard JE, Kane MA, Hadler SC. Global control of hepatitis B through vaccination: the role of hepatitis B vaccine in the expanded programme on immunization. Rev Infect Dis 1989;2:S574-5.
3. 3. Van Damme P, Matheï C, Thoelen S, Meheus A, Safary A, André F. Inactivated hepatitis A vaccine: rationale and clinical assessment of the safety and immunogenicity. J Med Virol 1994;44:435-41.
4. 4. Keefe EB, Iwarson S, McMahon BJ, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 1998;27:881-6.
5. 5. André F. Overview of 5-year clinical experience with a yeast derived hepatitis B vaccine. Vaccine 1990;8:S74-8.
6. 6. Vellinga A, Van Damme P, Weyler J, Vranckx R, Meheus A. Long term effectiveness of hepatitis B vaccination in mentally retarded: effectiveness after 11 years. Vaccine 1999;17:602-6.
7. 7. Diaz Mitoma F, Parsons J, Law B. Feasibility of the administration of pediatric doses of hepatitis A and hepatitis B vaccines as a single, combined injection in children and adolescents. Ped Infect Dis J 1999;18:109-14.
8. 8. Leroux-Roels G, Moreau E, Desombere I, Safary A. Safety and immunogenicity of a combined hepatitis A and B vaccine in young healthy adults. Scand J Gastroenterol 1996;31:1027-31.
9. 9. Thoelen S, Van Damme P, Leentvaar-Kuypers A, Leroux-Roels G, Bruguera M, Frei PC, et al. The first combined vaccine against hepatitis A and B: an overview. Vaccine 1999;17:1657-62.
10. 10. Ambrosch F, Wiedermann G, Andre F, Delem A, Gregor H, Hofman H, et al. Clinical and immunological investigation of a new combined hepatitis A and hepatitis B vaccine. J Med Virol 1994;44:452-6.
11. 11. Leroux-Roels G, Moreau E, Desombere I, Safary A. Safety and immunogenicity of a combined hepatitis A and hepatitis B vaccine in young healthy adults. Scand J Gastroenterol 1996;31:1027-31.
12. 12. Marsano LS, West DJ, Chan I, Hesley TM, Cox JC, Hackworth V, Greenberg RN. A two-dose hepatitis B vaccine regimen: proof of priming and memory responses in young adults. Vaccine 1998;16:624-9.